Hepatitis C virus genotype does not affect patient survival among renal transplant candidates

Natov, S; Lau, Johnson Y.N.; Ruthazer, Robin; Schmid, Christopher H.; Levey, Andrew S.; Pereira, Brian J.G.

doi:10.1046/j.1523-1755.1999.00594.x

Cited by 62 publications

(28 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(31,32), but mixed infection has not been associated with an increased mortality (33). However, the possibilities of superinfection in our study might be limited because genotype 1b is the most frequent in our area.…”

Section: Discussionmentioning

confidence: 61%

Long-Term Experience With Kidney Transplantation From Hepatitis C-Positive Donors Into Hepatitis C-Positive Recipients

Morales

Campistol

Domínguez‐Gil

et al. 2010

American Journal of Transplantation

View full text Add to dashboard Cite

Kidney transplantation from hepatitis C virus (HCV)antibody positive donors (HCVD+) into HCV antibody positive recipients (HCVR+) is controversial. We implemented this policy in our units in 1990. Herein, we report the long-term safety of this strategy. From March 1990 to March 2007, 162 HCVR+ received a kidney from HCVD+ (group 1) and 306 from HCVD− (group 2) in our units. Mean follow-up was 74.5 months. Five-and 10-year patient survival was 84.8% and 72.7% in group 1 vs. 86.6% and 76.5% in group 2 (p = 0.250). Three deaths in group 1 and two in group 2 were liver-disease related. Five-and 10-year graft survival was 58.9% and 34.4% versus 65.5% and 47.6% respectively (p = 0.006) while death-censored graft survival was 69% and 47% versus 72.7% and 58.5% (p = 0.055). Decompensated chronic liver disease was similar: 10.3% versus 6.2%. Cox-regression analysis could not identify the donor's HCV serology as a significant risk factor for death, graft failure and severe liver disease in HCVR+. In conclusion, long-term outcome of HCVR+ transplanted with kidneys from HCVD+ seems good in terms of patient survival, graft survival and liver disease. HCVD+ was not a significant risk factor for mortality, graft failure and liver disease among HCVR+. These data strongly suggest that the use of kidneys from HCVD+ in HCVR+ is a safe long-term strategy that helps to prevent kidney loss.

show abstract

Section: Discussionmentioning

confidence: 61%

Long-Term Experience With Kidney Transplantation From Hepatitis C-Positive Donors Into Hepatitis C-Positive Recipients

Morales

Campistol

Domínguez‐Gil

et al. 2010

American Journal of Transplantation

View full text Add to dashboard Cite

show abstract

“…There are no recommendations in the current literature to limit HCV þ donation to genotype 1 patients. 39 We also could not determine whether patients were treated with IFN before transplantation and what their responses were.…”

Section: Discussionmentioning

confidence: 99%

Equal 3-Year Outcomes for Kidney Transplantation Alone in HCV-Positive Patients With Cirrhosis

Parsikia

Campos

Khanmoradi

et al. 2015

International Surgery

View full text Add to dashboard Cite

Kidney transplantation alone in clinically compensated patients with cirrhosis is not well documented. Current guidelines list cirrhosis as a contraindication for kidney transplantation alone. This is an Institutional Review Board-approved retrospective study. We report our experience with a retrospective comparison between transplants in hepatitis C virus-positive (HCV þ ) patients without cirrhosis and HCV þ patients with cirrhosis. All of the patients were followed for at least a full 3-year period. All of the deaths and graft losses were recorded and analyzed using Kaplan-Meier methodology. One-and three-year cumulative patient survival rates for noncirrhotic patients were 91% and 82%, respectively. For cirrhotic patients, one-and three-year cumulative patient survival rates were 100% and 83%, respectively (P ¼ NS). One-and three-year cumulative graft survival rates censored for death were 94% and 81%, and 95% and 82% for the noncirrhosis and cirrhosis groups, respectively (P ¼ NS). Comparable patient and allograft survival rates were observed when standard kidney allograft recipients were analyzed separately. This study is the longest follow-up document in the literature showing that HCV þ clinically ompensated patients with cirrhosis may undergo kidney transplantation alone as a safe and viable practice.

show abstract

“…This practice can shorten waiting times for hepatitis C infected kidney transplant candidates on the waiting list. However, the risk of super-infection remains, as described in two single center studies [15,19].…”

Section: Renal Transplant Patientsmentioning

confidence: 99%

Management of Hepatitis C in Patients with Chronic Kidney Disease

Al-Freah

Zeino

Heneghan

2011

Curr Gastroenterol Rep

View full text Add to dashboard Cite

Chronic kidney disease represents a global health problem. Chronic hepatitis C virus (HCV) infection is prevalent in patients with end stage renal disease (ESRD) on hemodialysis (HD) and in renal transplant recipients with significant impact on morbidity and mortality. Furthermore, HCV can cause various forms of glomerulopathy with the predominant type being cryglobulinemia associated membranoproliferative glomerulonephritis. Liver enzymes are traditionally used as markers of liver injury; however, there is wide variation in aminotransferase levels in patients with ESRD. Therefore, diagnosis of chronic hepatitis C (CHC) in patients with ESRD is based on HCV antibody testing and further confirmation with polymerase chain reaction testing. Current standard therapy for CHC is composed of pegylated interferon and ribavirin. However, this combination is challenging in patients with ESRD due to its tolerability. We describe in this review relevant issues in epidemiology, diagnosis and management of CHC in ESRD, HD and renal transplant recipients.

show abstract

Hepatitis C virus genotype does not affect patient survival among renal transplant candidates

Abstract: The results of this study suggest that the type and number of HCV genotypes may not have a significant impact on survival among ESRD patients.

Cited by 62 publications

References 39 publications

Long-Term Experience With Kidney Transplantation From Hepatitis C-Positive Donors Into Hepatitis C-Positive Recipients

Long-Term Experience With Kidney Transplantation From Hepatitis C-Positive Donors Into Hepatitis C-Positive Recipients

Equal 3-Year Outcomes for Kidney Transplantation Alone in HCV-Positive Patients With Cirrhosis

Management of Hepatitis C in Patients with Chronic Kidney Disease

Contact Info

Product

Resources

About